Pfizer
$27.80Change from previous close: −1.14%Absolute change: −$0.32
At a glance
- Revenue growth
- −1.65%
- 2025 vs 2024
- Net income growth
- −3.24%
- 2025 vs 2024
- Net margin
- 12.4%
- 2024: 12.6%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 11,704 | 12,744 | 8,700 | 29,267 | 32,580 | 14,403 | 12,588 | 15,827 | 16,802 | 16,192 |
| Depreciation and amortization | 6,554 | 6,994 | 6,258 | 5,028 | 5,104 | 4,664 | 5,715 | 6,112 | 6,178 | 5,550 |
| Capital expenditure | -2,629 | -2,909 | -3,907 | -3,236 | -2,711 | -2,226 | -2,046 | -1,984 | -1,956 | -1,823 |
| Investing cash flow | -1,351 | 2,652 | -32,278 | -15,783 | -22,546 | -4,271 | -3,945 | 4,525 | -4,740 | -7,791 |
| Financing cash flow | -10,304 | -17,140 | 26,066 | -14,834 | -9,816 | -9,649 | -8,485 | -20,441 | -13,350 | -9,228 |
| Dividends paid | -9,771 | -9,512 | -9,247 | -8,983 | -8,729 | -8,440 | -8,043 | -7,978 | -7,659 | -7,317 |
| Share repurchases | — | 0.0 | 0.0 | -2,000 | 0.0 | — | -8,865 | -12,198 | -5,000 | -5,000 |
| Debt issued | 9,678 | 8,907 | 38,517 | 3,891 | 997 | 17,574 | 23,948 | 8,685 | 15,160 | 18,448 |
| Debt repaid | -9,752 | -16,066 | -2,572 | -7,407 | -2,100 | -30,329 | -15,184 | -9,620 | -16,101 | -15,842 |
| Effect of exchange rates | 41.0 | -66.0 | -40.0 | -165 | -59.0 | -8.0 | -32.0 | -116 | 53.0 | -215 |
| Net change in cash | 90.0 | -1,810 | 2,449 | -1,515 | 159 | 475 | 125 | -205 | -1,235 | -1,041 |
| Free cash flow | 9,075 | 9,835 | 4,793 | 26,031 | 29,869 | — | — | — | — | — |
| Levered free cash flow | 13,430 | 12,279 | 1,666 | 25,486 | 30,940 | 10,761 | 14,192 | 1,290 | 13,287 | 12,952 |